The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

Acute myeloid leukemia (AML) is a cancer of immature blood cells. When the early myeloid cell matures normally, it will become either a mature white blood cell, red blood cell, or platelet.

and cell death. Abnormalities in tyrosine kinases are common in AML, and constitute an attractive therapeutic target. An example is given by the balanced chromosomal translocations (TEL-Abl ...

Increased mixed chimerism, as detected by AlloHeme, could predict post-transplant relapse “with a high degree of accuracy,” said Monzr M. Al Malki, MD.